ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue47,15941,09750,561
Cost of Revenue---
Gross Profit47,15941,09750,561
Operating Expenses
Research Development382,392276,495190,249
Selling General and Administrative89,35460,61044,526
Non Recurring--220,766
Total Operating Expenses---
Operating Income or Loss-424,587-296,008-404,980
Income from Continuing Operations
Total Other Income/Expenses Net14,4795,9354,376
Earnings Before Interest and Taxes-410,108-290,073-400,604
Interest Expense---
Income Before Tax-410,108-290,073-400,604
Income Tax Expense---40,209
Minority Interest---
Net Income From Continuing Ops-410,108-290,073-360,395
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-410,108-290,073-360,395
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-410,108-290,073-360,395